Lexeo Therapeutics Inc LXEO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $9.11
- Day Range
- $8.52–9.36
- 52-Week Range
- $8.39–22.33
- Bid/Ask
- $8.23 / $8.77
- Market Cap
- $286.31 Mil
- Volume/Avg
- 230,302 / 346,262
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 69
- Website
- https://www.lexeotx.com
Comparables
Valuation
|
Metric
|
LXEO
|
CTNM
|
KROS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.73 | 2.01 | 5.23 |
Price/Sales | — | — | 7,393.47 |
Price/Cash Flow | — | — | — |
Price/Earnings
LXEO
CTNM
KROS
Financial Strength
|
Metric
|
LXEO
|
CTNM
|
KROS
|
|---|---|---|---|
Quick Ratio | 9.27 | 58.48 | 19.17 |
Current Ratio | 9.38 | 58.92 | 20.37 |
Interest Coverage | −474.89 | — | — |
Quick Ratio
LXEO
CTNM
KROS
Profitability
|
Metric
|
LXEO
|
CTNM
|
KROS
|
|---|---|---|---|
Return on Assets (Normalized) | −52.93% | −18.15% | −33.90% |
Return on Equity (Normalized) | −226.96% | −871.68% | −36.95% |
Return on Invested Capital (Normalized) | −174.12% | −892.99% | −35.57% |
Return on Assets
LXEO
CTNM
KROS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rwgvnkckrk | Rnvx | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hjjpdszx | Jxqyvqx | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dpzbsynk | Vwlfb | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Npdxsvby | Rkgrzz | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Yqrpndl | Nkpv | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Sfwctlydg | Pmcrj | $29.2 Bil | |||
| Moderna Inc
MRNA
| Fnrgjrst | Gfldg | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Wstfrwbqx | Vpmh | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Tgxtwbncg | Zgmhs | $13.2 Bil | |||
| Incyte Corp
INCY
| Rmfbznrb | Tbqxpwh | $13.0 Bil |
United States